Benzimidazole-2-piperazine compound, pharmaceutical composition of compound and preparing method and application of pharmaceutical composition

A technology of benzimidazoles and compounds, applied in the field of poly(ADP-ribose) polymerase (PARP) inhibitors, can solve problems such as inability to perform repair process

Active Publication Date: 2014-08-27
SHANGHAI HUILUN BIOLOGICAL TECH CO LTD
View PDF3 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

PARP without poly(ADP-ribosylation) modification cannot dissociate from the DNA damage site, which will cause othe

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzimidazole-2-piperazine compound, pharmaceutical composition of compound and preparing method and application of pharmaceutical composition
  • Benzimidazole-2-piperazine compound, pharmaceutical composition of compound and preparing method and application of pharmaceutical composition
  • Benzimidazole-2-piperazine compound, pharmaceutical composition of compound and preparing method and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0104] Compound (1): 3-(4-(4-carbamoyl-1hydro-benzimidazol-2-yl)piperazine-1-carbonyl)pyrrolidine-1-tert-butyl carbonate, the reaction formula is as follows:

[0105]

[0106] Step 1: Compound a: 2-oxo-2,3-dihydro-1hydro-benzimidazole-4-carboxylic acid methyl ester

[0107] Add carbonyl diimidazole (1.56g, 9.6mmol) to an anhydrous tetrahydrofuran solution (20mL) with methyl 2,3-diaminobenzoate (0.8g, 4.8mmol) dissolved, heat to reflux, and react for 8 hours After cooling, the solvent was removed under reduced pressure, and the residue was separated by flash column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain a pale yellow solid compound a (0.3 g, yield 33%). MS(ESI)m / z:[M+H] + =193.

[0108] Step 2: Compound b: 2-chloro-1hydro-benzimidazole-4-carboxylic acid methyl ester

[0109] Compound a (1.1g, 5.7mmol) was added to phosphorus oxychloride (8mL), heated to reflux, reacted for 8 hours and then cooled, the solvent was removed under reduced pressure, and the residue...

Embodiment 2

[0117] Compound (2): (S)-2-(4-(4-carbamoyl-1hydro-benzimidazol-2-yl)piperazine-1-carbonyl)pyrrolidine-1-tert-butyl carbonate

[0118]

[0119] A method similar to the preparation of compound (1) in Example 1 was adopted, that is, compound (2) (21 mg, yield 11%) was obtained by condensation of compound d with (S)-1-tert-butoxycarbonylpyrrolidine-2-carboxylic acid. MS(ESI)m / z:[M+H] + =443. 1 H NMR (300MHz, DMSO-d6): δ11.99(br,1H), 9.10(br,1H), 7.61(d,1H,J=7.5Hz), 7.51(br,1H), 7.33(d,1H) ,J=7.5Hz),6.98(t,1H,J=7.5Hz),4.70-4.63(m,1H),3.70-3.56(m,10H),2.19-2.11(m,2H),1.79-1.73( m, 2H), 1.36 (s, 9H).

Embodiment 3

[0121] Compound (3): (R)-2-(4-(4-carbamoyl-1hydro-benzimidazol-2-yl)piperazine-1-carbonyl)pyrrolidine-1-tert-butyl carbonate

[0122]

[0123] Using a method similar to the preparation of compound (1) in Example 1, compound (3) (18 mg, yield 10%) was obtained by condensation of compound d and (R)-1-tert-butoxycarbonylpyrrolidine-2-carboxylic acid. MS(ESI)m / z:[M+H] + =443. 1 H NMR (300MHz, DMSO-d6): δ11.84(br,1H), 9.10(br,1H), 7.61(d,1H,J=7.5Hz), 7.51(br,1H), 7.32(d,1H) ,J=7.5Hz),6.99(t,1H,J=7.5Hz),4.69-4.65(m,1H),3.70-3.55(m,10H),2.21-2.09(m,2H),1.79-1.74( m, 2H), 1.29 (s, 9H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

Description

Technical field [0001] The invention relates to a benzimidazole-2-piperazine derivative, a preparation method thereof, a pharmaceutical composition containing the derivative, and its use as a therapeutic agent and as a poly(ADP-ribose) polymerase (PARP) inhibitor . Background technique [0002] Chemotherapy drugs and ionizing radiation therapy are two common methods of treating cancer. Both of these treatment methods can induce DNA single-strand and / or double-strand breaks and thus produce cytotoxic effects. Target tumor cells die due to chromosomal damage. As an important result of responding to DNA damage signals, the cell cycle control site signals are activated, which aims to protect cells from mitosis in the case of DNA damage to avoid cell damage. In most cases, tumor cells have a high rate of proliferation while showing signal defects at cell cycle control sites. Therefore, it can be inferred that there is a specific DNA repair mechanism in tumor cells that can quickly ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D403/12C07D403/14C07D401/14C07D401/12A61K31/496A61K31/551A61P9/00A61P31/00A61P29/00A61P9/10A61P25/00A61P7/00A61P35/00
CPCC07D401/12C07D401/14C07D403/12C07D403/14
Inventor 樊兴秦继红
Owner SHANGHAI HUILUN BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products